AbbVie VP of Oncology Discovery Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to discovery and development efficiencies. Listen now.
Learn more about the importance of sterile filtration and how sterile filters are validated by the manufacturer, and review the process and value of selecting the best prefilter to improve final sterile filtration performance.
As the field of biologics increases its focus on identifying new diseases to target and novel constructs to treat them, innovative administration devices are once again in the spotlight.
We demonstrate how to reduce the time taken to develop a binding ELISA from over five runs to just two runs for both IgG monoclonal antibodies and Fc fusion proteins.
Realizing the potential of next-generation molecules calls on appropriate expression technologies and development processes that can facilitate their path to market.
Workhouse resins developed in the 1980s are still used in many processes, but are you missing out on better productivity and performance? How do you know which resin to use in new projects?
Understand how the supply chain experience, severely affected by COVID-19, involving global workforce disruption, surging demand, and drug shortage notices, is shaping attitudes toward resilience.
A pharmaceutical company sought a CMO partner with commercial manufacturing capabilities and expertise and exemplary quality systems to find a cost-effective process to produce the API for a new drug.
Drs. Joachim Klein and Rebecca Michael from Lonza Pharma & Biotech answer attendee questions from a recent webinar about Lonza’s options for expressing and manufacturing complex biologic drugs.
